Cancer Immunotherapy Developer Cellectis Eyes $115M IPO
Cancer treatment developer Cellectis SA on Friday filed to raise up to $115 million in its U.S. initial public offering, as the France-based company eyes investor excitement surrounding the promise of...To view the full article, register now.
Already a subscriber? Click here to view full article